XML 41 R24.htm IDEA: XBRL DOCUMENT
v3.26.1

LICENSING AGREEMENTS (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 28, 2022 | Dec. 28, 2020 | May 17, 2017 | Dec. 31, 2025 | Dec. 31, 2024 | Aug. 31, 2023 | Sep. 30, 2021 | Jan. 31, 2021 | Dec. 31, 2020 | Dec. 12, 2020 | Feb. 02, 2016
Number of shares |  |  |  |  |  |  |  |  |  |  | 43,112
Additional CMH payment |  |  |  | $ 50,000 |  |  |  |  |  |  |
Obligation due under agreement through the issuance of common stocks |  |  |  | 300,000 |  |  |  |  |  |  |
Payment for clinical trial |  |  |  | 200,000 |  |  |  |  |  |  |
Common stock value |  |  |  | 3,144 | $ 1,749 |  |  |  |  |  | $ 100,000
Patents gross |  |  |  | $ 300,000 |  |  |  |  |  |  |
Total obligation under the agreement |  |  |  |  |  |  | $ 300,000 |  | $ 100,000 | $ 300,000 |
Initial payment of obligation |  |  |  |  |  |  | $ 40,000 |  | $ 50,000 | $ 50,000 |
Balance of obligation, description |  |  |  | The remaining portion of the $300,000 obligation was paid in cash in 2020 |  |  |  |  |  |  |
Remaining portion of obligation |  |  |  |  |  | $ 100,000 |  |  |  |  |
Amortization |  |  |  | $ 123,327 | 110,452 |  |  |  |  |  |
Amortization expenses |  |  |  | $ 46,523 | $ 45,940 |  |  |  |  |  |
Common stock shares |  |  |  | 3,701,668 | 1,748,428 |  |  |  |  |  |
Description of payment on conversion basis |  |  | Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date |  |  |  |  |  |  |  |
Description for the consecutive trading days |  |  | In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles. |  |  |  |  |  |  |  |
Payments upon completion of the IRB clinical trial |  |  | $ 200,000 |  |  |  |  |  |  |  |
Payments in the event of commercialization of technology |  |  |  | $ 300,000 |  |  |  |  |  |  |
Licensing Agreements [Member] |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  |  | 0 |  |  |  |  |  |  |
Payments upon dosing of the first patient in Phase 3 clinical trial |  |  |  | 100,000 |  |  |  |  |  |  |
License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Amortization expenses |  |  |  | 861 | $ 1,172 |  |  |  |  |  |
Carrying value of patent |  |  |  | 0 |  |  |  |  |  |  |
Jadi Cell [Member] |  |  |  |  |  |  |  |  |  |  |
Pyment for license fees | $ 250,000 | $ 250,000 |  |  |  |  |  |  |  |  |
Common stock shares | 18,018 |  |  |  |  |  |  |  |  |  |
StemSpine LLC [Member] |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  |  | 10,861 | 10,000 |  |  |  |  |  |
Carrying value of patent |  |  |  | $ 14,139 |  |  |  |  |  |  |
Expiration period of finite-lived intangible assets |  |  |  | May 19, 2027 |  |  |  |  |  |  |
Amortization |  |  |  | $ 10,000 |  |  |  |  |  |  |
Option Warrant [Member] |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  |  | 25,075 | 25,000 |  |  |  |  |  |
Carrying value of patent |  |  |  | 124,925 |  |  |  |  |  |  |
Amortization |  |  |  | 25,000 |  |  |  |  |  |  |
Initial payment |  |  | 100,000 |  |  |  |  |  |  |  |
Payments upon dosing of the first patient in Phase 3 clinical trial |  |  | 400,000 | 100,000 |  |  |  |  |  |  |
Payments upon dosing of the first patient first patient in a Phase 1-2 clinical trial |  |  | $ 200,000 |  |  |  |  |  |  |  |
ImmCelz Patent [Member] |  |  |  |  |  |  |  |  |  |  |
Patents gross |  |  |  | $ 200,000 |  |  |  |  |  |  |
Common stock, shares |  |  |  |  |  |  | 8,466 | 8,929 |  | 667 |
Discount rate |  |  |  | 25.00% |  |  |  |  |  |  |
Amortization expenses |  |  |  | $ 19,989 | 5,038 |  |  |  |  |  |
Interest rate |  |  |  | 5.00% |  |  |  |  |  |  |
Carrying value of patent |  |  |  | $ 171,659 |  |  |  |  |  |  |
Exercise price |  |  |  | $ 0.00 |  |  |  |  |  |  |
Amortization |  |  |  | $ 20,000 |  |  |  |  |  |  |
EDI Patent [Member] |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  |  | 9,972 | 9,972 |  |  |  |  |  |
Carrying value of patent |  |  |  | 1,042 |  |  |  |  |  |  |
Amortization |  |  |  | 1,042 |  |  |  |  |  |  |
IND [Member] |  |  |  |  |  |  |  |  |  |  |
Patents gross |  |  |  | 100,000 |  |  |  |  |  |  |
Amortization |  |  |  | 9,989 | $ 10,016 |  |  |  |  |  |
Carrying value of patent |  |  |  | 77,495 |  |  |  |  |  |  |
Amortization |  |  |  | 10,000 |  |  |  |  |  |  |
Patents [Member] |  |  |  |  |  |  |  |  |  |  |
Carrying value of patent |  |  |  | 17,971 |  |  |  |  |  |  |
Amortization |  |  |  | $ 17,971 |  |  |  |  |  |  |

X
- References No definition available. + Details
Name: | celz_AdditionalCMHPaymentAmount
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | celz_AmortizationExpense
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_AmortizationExpenses
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_DescriptionForTheConsecutiveTradingDays
Namespace Prefix: | celz_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_ExpirationPeriodOfFiniteLivedIntangibleAssets
Namespace Prefix: | celz_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_InitialPaymentsToAcquireIntangibleAssets
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_IssuanceOfCommonStockShares
Namespace Prefix: | celz_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | celz_NumberOfShareExchange
Namespace Prefix: | celz_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | celz_ObligationDueThroughIssuanceOfCommonStocks
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_OperatingLeaseObligationsCurrent
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | celz_OtherIntangibleAssetsCarryingValueNet
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | celz_PaymentForClinicalTrialAmount
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_PaymentsInTheEventOfCommercializationOfTechnology
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_PaymentsUponCompletionOfIrbClinicalTrial
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_PaymentsUponDosingOfFirstPatientInPhase3ClinicalTrial
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_PaymentsUponDosingOfTheFirstPatientFirstPatientInAPhaseClinicalTrial
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | celz_PerformanceObligationAndPayment
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | celz_RemainingPortionOfObligationPaidInCash
Namespace Prefix: | celz_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 55 -Paragraph 40 -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Description of basis for conversion of convertible common stock. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockConversionBasis
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (01)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_CommonStockValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details
Name: | us-gaap_DepreciationAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_FiniteLivedPatentsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other. + References No definition available. + Details
Name: | us-gaap_OtherIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash outflow for fees classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Stated interest rate of the subordinated debt. + References No definition available. + Details
Name: | us-gaap_SubordinatedBorrowingInterestRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Describes the nature of an unconditional purchase obligation that is not recognized as a liability on the balance sheet. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 + Details
Name: | us-gaap_UnrecordedUnconditionalPurchaseObligationDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_WarrantExercisePriceIncrease
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percent discount applied to worker's compensation reserve liability to reduce the reserve to present value. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480081/944-40-50-6 + Details
Name: | us-gaap_WorkersCompensationDiscountPercent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=celz_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=celz_JadiCellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=celz_StemSpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=celz_WarrantssMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=celz_ImmCelzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=celz_EDIPatentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=celz_INDPatentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |